Roche Holding AG (RO)

246.00
0.00(0.00%)
  • Volume:
    0
  • Bid/Ask:
    245.80/246.40
  • Day's Range:
    244.80 - 248.00
  • Type:Equity
  • Market:Germany
  • ISIN:CH0012032113
  • WKN:851311

RO Overview

Prev. Close
245.8
Day's Range
244.8-248
Revenue
-
Open
246.4
52 wk Range
-
EPS
-
Volume
0
Market Cap
305.9B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
2,891
P/E Ratio
-
Beta
-
1-Year Change
0%
Shares Outstanding
854,260,903
Next Earnings Date
-
What is your sentiment on Roche Holding AG?
or
Market is currently closed. Voting is open during market hours.

Roche Holding AG News

Roche Holding AG Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving Averages
Technical Indicators
Summary

Roche Holding AG Company Profile

Roche Holding AG Company Profile

Employees
101465

Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women’s health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza, as well as SemaThera Inc. to develop biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors, as well as with Surface Oncology, Inc. to evaluate SRF388. The company was founded in 1896 and is headquartered in Basel, Switzerland.

Read More
  • A large pharmaceutical company, by the name of R. , is pushing down the value of the Spanish company's Pharmamar share price through the funds Consonance Capital and Great Point Partners, so that the biotech company accepts its offer of more than 4500 million dollars.According to this pharma, Pharmamar's products have a great future in oncology and virology, and would be fully engaged in its search for new drugs.
    1
    • 13.11.2020. CHMP recommends EU approval of Roche’s Xofluza® (baloxavir marboxil) for the treatment of influenza. This CHMP recommendation brings patients with influenza one step closer to potentially benefiting from Xofluza’s oral one-dose regimen, setting adults and adolescents on the path to feeling better sooner compared to placebo,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We believe that access to effective antivirals for influenza, and particularly their use in the prophylactic setting, could help reduce the strain of the COVID-19 pandemic on healthcare systems in Europe.
      0
      • Just like Biolidics. they get approval for Covid19 tests kits in USA
        0
        • i dont know
          0
          • is the historical price adjusted for stock splits?
            0
            • i dont know
              0
          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.